DUBLIN, May 8, 2020 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Allergan plc (NYSE: AGN) ("Allergan") announced…
LONDON--(BUSINESS WIRE)-- #ChemicalPeelMarket--The chemical peel market is poised to grow by 62.78 mn during 2020-2024, according to Technavio
DUBLIN, May 7, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that The Allergan Foundation has fast-tracked another $2 million dollars in charitable grants for community organizations responding to the COVID-19 pandemic. The new grants double The Allergan Foundation's total…
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DUBLIN, May 6, 2020 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Allergan plc (NYSE: AGN) ("Allergan") today…
AbbVie’s (ABBV) plan to close the $63 billion Allergan (AGN) deal this month appears on track following the announcement that they have received … The post AbbVie Scores US Antitrust Approval for $63B Allergan Deal appeared first on Smarter Analyst .
AbbVie, which is expecting to close the acquisition of Allergan in this month, reported its first quarter 2020 earnings results last Friday. The drug manufacturer’s quarterly results surpassed the market’s estimates as COVID-19 related lockdown and social distancing made patients and pharmacies to build up some additional inventory of AbbVie drugs to ensure they had […]
DUBLIN--(BUSINESS WIRE)--The "US Hyaluronic Acid-Based Dermal Fillers Market 2025" report has been added to ResearchAndMarkets.com's offering. The US hyaluronic acid-based dermal fillers market is estimated to grow at a CAGR of nearly 7% during the forecast period. This market growth owing to the rising demand for cosmetic procedures coupled with high consciousness about facial rejuvenation and an increasing number of medical spas in the region. A significant rise in cosmetic procedures was wit
DUBLIN, April 28, 2020 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Allergan plc (NYSE: AGN) ("Allergan") announced…
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for patent applications covering the formulation of the 72 mcg dose of LINZESS® (linaclotide) and methods of using the formulation. The patent applications are expected to issue in 2020 and expire in 2031. LINZESS is approved and marketed in the United States for the treatment of adult men and women suffering from irrit
Before the novel coronavirus changed everything, AbbVie’s buyout of Allergan stock made sense. Now, it’s a big question mark.
DUBLIN , April 27, 2020 /PRNewswire/ -- The "Depression - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. This pipeline guide provides an overview of the Depression (Central Nervous System) pipeline landscape. It provides comprehensive information on the therapeutics under development for Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. It also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 2, 16, 36, 42, 4, 86, 22 and 5 respectively.
Dan Davidowitz — the lead portfolio manager of the focus growth strategy at Polen Capital — and Jeff Mueller — co-portfolio manager of the global growth strategy at the firm — aren't your typical value investors. The duo makes it a point to focus on competitive advantages, margins of safety, strong balance sheets, limited competition, secular tailwinds, and long-term growth when vetting companies. They share five competitive advantages they look for before an investment gets added to their portfolio — and the more, the better. The pair also share three recent stocks they've been buying in the midst of recent market turmoil. Click here for more BI Prime stories. Dan Davidowitz and Jeff Mueller are two value investors that don't adhere to the traditional definition of the distinction. At Polen Capital — where the duo oversee in excess of $37 billion — Davidowitz serves as the cohead of the large company growth team and the lead portfolio manager of the firm's bellwether focus growth strategy.
LONDON--(BUSINESS WIRE)-- #PruritusTherapeuticMarket--The pruritus therapeutic market size has the potential to grow by USD 3.63 billion during 2020-2024
DUBLIN--(BUSINESS WIRE)--The "Aesthetic Lasers and Energy Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering. The global aesthetic lasers and energy devices market reached a value of US$ 3,786 Million in 2019. Aesthetic lasers and energy devices are the medical devices that are used for numerous cosmetic procedures to treat skin defects and improve the physical appearance of an individual. U
ALLERGAN PLC : News, information and stories for ALLERGAN PLC | Nyse: AGN | Nyse
----------------------------------------------------------- N/A ----------------------------------------------------------- Is a Supplemental Form 8 attached? NO… | March 24, 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) …
Allergan (AGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Allergan's (AGN) Durysta (bimatoprost) gets FDA approval to reduce intraocular pressure in patients with open-angle glaucoma.
Editas (EDIT) and Allergan are co-developing a CRISPR-based candidate, AGN-151587, for treating Leber congenital amaurosis 10 (LCA10), an inherited form of blindness.
Allergan Plc Released 11:03 05-Mar-2020 …
Allergan PLC Released 11:52 04-Mar-2020 …
Allergan PLC has agreed to pay nearly $51.3 million to resolve allegations that the drugmaker violated antitrust laws by improperly trying to delay U.S. regulatory approval of generic competitors for its dry-eye medication Restasis.
DUBLIN, Feb. 25, 2020 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company with a more than 70-year heritage in ophthalmology, will present new data from investigational Bimatoprost Sustained-Release (SR) at the Annual Meeting of the American Glaucoma Society…
MARLBOROUGH, Mass., Feb. 20, 2020 /PRNewswire/ -- BTL Industries, Inc. ("BTL") today announced it has filed a lawsuit against Allergan plc, Allergan USA, Inc., Allergan, Inc., and Zeltiq Aesthetics, Inc. The lawsuit alleges a wide-ranging false and misleading advertising campaign launched…
LONDON--(BUSINESS WIRE)-- #Healthcare--The regenerative medicine market is poised to grow by USD 9.55 billion during 2020-2024, progressing at a CAGR of over 20% during the forecast period
Allergan Released 11:30 17-Feb-2020 …
------------------------------------------------------- -------------------- If a connected EFM, name of offeree/offeror with which N/A connected… | February 11, 2020
Allergan Plc Released 11:31 11-Feb-2020 …
Botox, Juvederm fillers and Vraylar drive Allergan's (AGN) fourth-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.
Allergan (AGN) earnings for the pharmaceutical company's fourth quarter of 2019 have AGN stock up Monday after beating estimates.
Investors who owned stocks in the 2010s generally experienced some big gains. In fact, the SPDR S&P 500's (NYSE: SPY ) total return for the decade was 250.5%. But there’s no question some big-name stocks did much better than others along the way. Allergan’s Big Decade One stock that had plenty of highs and lows over the past decade is pharmaceutical giant Allergan plc (NYSE: AGN ). Allergan’s decade was defined by blockbuster deals and failed deals. Today’s Allergan actually started the 2010s as Irish company Actavis. In 2015, Actavis acquired Allergan and re-domiciled it in Ireland as part of a tax inversion deal that helped Allergan avoid paying U.S. taxes. As part of the deal, Actavis took over Allergan’s name. Actavis was subsequently blocked by the U.S. Treasury in 2016 from … Full story available on Benzinga.com
Regulatory Story Go to market news section …
Regulatory Story Go to market news section …
Allergan (AGN) Q4 results: Revenues: $4,351M (+6.6%). Key product sales: Botox: $1,020.2M (+7.9%); Restasis: $327.7M (-4.1%); Juvederm: $347.3M (+4.5%); Vr
By Micah Maidenberg Allergan PLC reported stronger-than-expected revenue and a smaller loss for the fourth quarter. The maker of Botox and other drugs on Monday reported $4.35 billion in… | February 10, 2020
Shares of Allergan PLC rose 1% in premarket trading Monday, after the drug maker reported a fourth-quarter adjusted profit and revenue that beat…
Allergan plc AGN posted stronger-than-expected fourth quarter earnings Monday and said it expects its impending $63 billion takeover by AbbVie ABBV to close by the end of March.
Feb 7- AbbVie Inc on Friday forecast full-year earnings well above Wall Street estimates, as the U.S. drugmaker looks to new treatments and its pending acquisition of Allergan Plc to drive growth beyond 2023, when its cash cow Humira loses patent protection. AbbVie said it expects 2020 adjusted earnings of $9.61 to $9.71 per share, above analysts' estimates of…
Allergan's (AGN) key products like Botox are likely to have provided top-line support in Q4 as loss of exclusivity of several products hurts sales.
DUBLIN, Feb. 3, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced today its Be The Difference philanthropic program supporting children and their families who may benefit from treatment with BOTOX® (onabotulinumtoxinA) for pediatric upper limb spasticity. BOTOX® is approved to treat…
Global biopharmaceutical company Allergan has opened a new €160m state-of-the-art facility at its Westport campus.
Allergan (AGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Allergan (AGN) to divest autoimmune candidate, brazikumab and drug Zenpep in connection with its pending merger with AbbVie.
Irish-domiciled Allergan said this new investment would increase its workforce across the Republic beyond 2,000
The maker of Botox, Allergan, is opening a new €160m biologics facility at its campus in Westport in Co Mayo.
Looking to expand in medical nutrition, Nestle (OTCPK:NSRGY) is buying Allergan's (NYSE:AGN) Zenpep, which had sales of $237M in 2018. The product caters t
By Ian Walker AstraZeneca said Monday that it will take back the global rights to brazikumab after ending a license deal with Allergan PLC. AstraZeneca said Allergen will fund the costs… | January 27, 2020
Nestlé today announced that it has entered into an asset purchase agreement with Allergan to acquire the gastrointestinal medication Zenpep. This move aims to expand the… | January 27, 2020
- ← Previous
- 1
- 2
- 3
- Next →